top 20 biologics 2009 rd pipeline news

1/26 La Merie S.L. | Email [email protected] | Internet www.lamerie.com

TOP 20 Biologics 2009 March 10, 2010 | Special Edition 1

TOP 20 Biologics 2009

• TOP 28 Blockbuster Biologics 2009

• TOP 14 Biologics Classes 2009

• Blockbuster Biologics 2009 by Class

• Other Antibody

• Selected Proteins

• Selected Peptides

Features:

March 10, 2010 Special Edition 1/2010

March 10, 2009

Subscribe now!

http://www.pipelinereview.com/joomla/index.php?option=com_yanc&Itemid=133&listid=1&action=subscribe



No. Previous

Year Class of Products 2009 sales

(US$ bln.) 2008 sales (US$ bln.)

Selected Branded Products

1 2 Major Cancer Antibodies 18.18 15.59 Rituxan/MabThera, Herceptin, Avastin, Erbitux, Vectibix

2 1 Anti-TNF Antibodies 18.10 16.36 Enbrel, Remicade, Humira, Cimzia

3 3 Insulin and Insulin Analogs 13.34 10.90 Humalog, Humulin, Lantus, Levemir, Novorapid, Actrapid, Novolin, Apidra

4 4 Erythropoietins 9.56 10.05 Aranesp, Procrit Eprex, Epogen, Neo-Recormon, ESPO, Dynepo, Binocrit

5 5 Interferon beta 6.06 5.35 Avonex, Rebif, Betaferon / Betaseron

6 7 Rec. Coagulation Factors 5.73 4.94 Novoseven, Kogenate, Helixate, Refacto, Advate, Recombinate, Benefix

7 6 G-CSF 5.16 5.18 Neulasta, Neupogen, Neutrogin, GRAN

8 11 Anti-Inflammatory Antibodies

3.12 2.29 Tysabri, Xolair, Orencia, Soliris, RoActemra, Arcalyst

9 9 Human Growth Hormone 2.89 2.68 Genotropin, Norditropin, Humatrope, Nutropin, Saizen, Serostim, Omnitrope

10 10 Interferon alpha 2.61 2.56 Pegasys, Peg-Intron, Intron A

11 8 Enzyme Replacement 2.42 2.80 Cerezyme, Fabrazyme, Aldurazyme, Myozyme, Replagal, Naglazyme, Elaprase

12 12 Ophthalmic Antibody

2.34 1.76 Lucentis

13 14 Follicle Stimulating Hormone

1.21 1.16 Gonal-f, Puregon/Follistim

14 13 Antiviral antibody 1.08 1.23 Synagis

Total: 91.78 82.85

Currency exchange rates as of March 10, 2010: 1 € = 1.35529 US$; 1 CHF = 0.926783 US$; 1 Yen = 0.011117 US$; 1 DKK = 0.18214 US$; 1 SEK = 0.13961 US$



TOP 20 Biologics in 2009 (by generic name)

# Product Name

Target / Mechanism of Action

Class of Compound

Company Product Category

Indication 2009 sales (vs 2008)

1 etanercept: Enbrel

TNF antagonist

Dimeric fusion protein of soluble TNF-R + Fc of Ig

Amgen & Wyeth & Takeda Pharmaceutical Co.

Antibody Rheumatoid arthritis and all other approved indications

Total: US$ 6,580 mln (6,490)

2 infliximab: Remicade

TNF alpha antagonist

Rec chimeric IgG1 mab

Centocor (J&J) & Schering-Plough & Mitsubishi Tanabe Pharma

Antibody Rheumatoid arthritis et al.

Total: US$ 5,934 mln (5,335)

3 bevacizu-mab: Avastin

VEGF Rec humanized mab

Genentech & Roche & Chugai

Antibody Metastatic colorectal cancer with 5-FU; 1st line NSCLC plus carboplatin & paclitaxel

Total: US$ 5,777 mln (4,484)

4 rituximab: Rituxan / MabThera

CD20 Rec chimeric full mab

Genentech; Biogen-IDEC, Roche

Antibody Non-Hodgkin's lymphoma (NHL) and all other approved indications

Total: US$ 5,653 mln (5,099)

5 adalimu-mab: Humira Pen


Rec fully human mab

Abbott & Eisai Antibody Rheumatoid arthritis et al.

Total: US$ 5,488 mln (4,521)

6 epoetin alfa: Epogen / Procrit / Eprex / ESPO

Erythropoietin receptor (EPO-R)

Rhu protein Amgen & Ortho Biotech / Janssen-Cilag (J&J) & Kyowa Hakko Kirin Pharma

Protein Renal anemia and all other approved indications

US$ 2.569 bln + half of US$ 438.4 mln + US$ 2.245 bln Total: US$ 5,033 mln (5,123)




# Product Name


Class of Compound



7 trastuzu-mab: Herceptin

HER2 Rec humanized mab

Genentech; Chugai, Roche

Antibody Her2 positive metastatic breast cancer et al.

Total: US$ 4,890 mln (4,384)

8 insulin glargine: Lantus

Insulin receptor

Rhu basal insulin analog for once-daily SC injection

Sanofi-Aventis Protein Type 1 and Type 2 diabetes

Total: US$ 4,185 mln (3,130)

9 pegfilgra-stim: Neulasta

G-CSF receptor

Pegylated rec methio-nyl human G-CSF

Amgen Protein Neutropenia Total: US$ 3,355 mln (3,318)

10 darbepo-etin alfa: Aranesp / NESP


Engineered variant of rhu protein AutoInjector

Amgen & Kyowa Hakko Kirin Pharma

Protein Anemia US$ 2.652 bln + half of US$ 438.4 mln Total: US$ 2,871 mln (3.344)

11 ranibizu-mab: Lucentis

VEGF Rec humanized Fab for intravitreal injection

Genentech & Novartis

Antibody Wet age-related macular degeneration (AMD)

Total: US$ 2,344 mln (1,761)

12 interferon beta-1a: Avonex

Interferon beta receptor

Rhu protein for IM injection once a week

Biogen Idec Protein Relapsing forms of multiple sclerosis

Total: US$ 2,323 mln (2,203)

13 interferon beta-1a: Rebif


Rhu protein (prefilled syringe)

Merck Serono Protein Relapsing forms of multiple sclerosis

Total: US$ 2,087 mln (1,699)




# Product Name


Class of Compound



14 rhu insulin: Actrapid (EU)/ Novolin (US)

Insulin receptor

Rhu insulin (short-acting) for injection, (S. cerevisiae)

Novo Nordisk Protein Type 1 and 2 diabetes

Total: US$ 2,066 mln (2,017)

15 rec Anti-hemophilic Factor: Advate

Coagulation factor VIII replacement

Rec full length factor VIII plasma / albumin free

Baxter Healthcare

Protein Hemophilia A

US$ 2,058 mln (> 1,500) Advate and Recombinate (in process of conversion)

16 insulin lispro: Humalog Mix 50:50 premix

Insulin receptor

Soluble rhu insulin ana-log (50 %) + insuline-protamine precipitate (50 %)

Eli Lilly Protein Type 1 and 2 diabetes

Total: US$ 1,959 mln (1,734)

17 insulin aspart: NovoLog NovoRapid

Insulin receptor

Rhu insulin analog (rapid-acting)

Novo Nordisk Protein Glycemic control in children and adults with diabetes mellitus

Total: US$ 1,780 mln (1,338)

18 interferon beta-1b: Betaseron / Betaferon


Rhu protein Berlex & Bayer Schering Pharma

Protein All relapsing forms of multiple sclerosis

Total: US$ 1,649 mln (1,449)

19 cetuximab: Erbitux

EGF-R Rec chimeric mab

Eli Lilly (from ImClone acq.) & BMS & Merck Serono

Antibody Metastatic colo-rectal carcinoma and other labels

Total: US$ 1,629 mln (1,470)

20 peginter-feron alfa-2a: Pegasys

Interferon alpha receptor

Pegylated rhu protein

Roche Protein Chronic hepatitis C virus infection + Copegus

Total: US$ 1,538 bln (1,408)




# Product Name


Class of Compound



21 epoetin beta: NeoRecor-mo / Epogin / Epoch


Rhu protein Roche Protein Renal anemia and all other approved indications

Total: US$ 1,450 mln (1,527) 971 + 479

22 filgrastim: Neupogen;

G-CSF receptor

Rhu protein Amgen Protein Neutropenia Total: US$ 1,341 bln (1,419)

23 eptacog alfa: NovoSeven

Induction of coagulation in the presence of alloantibodies to F. VIII

Rhu protein in BHK; now in room-temperature stable liquid formulation

Novo Nordisk Protein Prevention and treatment of hemorrhage in hemophiliacs with alloantibodies

Total: US$ 1,292 mln (1,127)

24 Rec Anti-hemophilic Factor: Kogenate FS

F. VIII substitution

Rhu protein formulated with sucrose (BHK)

Bayer Schering Pharma

Protein Hemophilia A Total: US$ 1,207 mln (1,074)

25 premix insulin aspart; NovoMix 50;

Insulin receptor

Soluble + protamine-crystallized rhu insulin analog


Total: US$ 1,187 mln (1,032)

26 palivizu-mab: Synagis

Epitope on RS virus

Rec humanized full mab

MedImmune Antibody Propylaxis of RSV infection

Total: US$ 1,082 mln (1.230)

27 natalizu-mab: Tysabri

Alpha4/beta1/7 integrin

Rec humanized IgG4 mab

Biogen Idec & Elan

Antibody RR multiple sclerosis

Total: US$ 1,060 mln (815)

28 human insulin: Humulin 50:50

Insulin receptor

Rhu insulin (mix isophane suspension)


Total: US$ 1,022 mln (1,063)



Group 1: Cancer Antibodies

ID No.

Product Name


Class of Compound


Indication R&D Stage

Message

1891

Avastin; bevacizumab

Vascular endothelial growth factor (VEGF)

Rec humanized mab

Roche Antibody 1st and 2nd line metastatic colorectal cancer with 5-FU-based chemotherapy

Mar-ket

Roche PR Feb 3, 2010 - 2009 worldwide sales of Avastin were CHF 6,222 mln (+ 21 % in local currency vs 2008) corresponding to US$ 5,777 mln

1825

Rituxan / MabThera; rituximab;

CD20 Rec chimeric full mab

Roche (Genentech) & Biogen-IDEC

Antibody Non-Hodgkin's B-Cell Lymphoma

Mar-ket

Roche PR Feb 3, 2010 - 2009 sales of CHF 6,087 mln (+ 6 % in local currencies vs 2008) corresponding to US$ 5,653 mln

1869

Herceptin; trastuzumab

HER2 Rec humanized mab

Roche (Genentech & Chugai)

Antibody Her2 positive metastatic breast cancer and all other approved indications

Mar-ket


1847

Erbitux; cetuximab; IMC-C225; EMD-271786

EGF-R Rec chimeric mab

Eli Lilly (from ImClone acquisition) & Bristol-Myers Squibb (BMS) & Merck Serono

Antibody Irinotecan refractory metastatic colorectal carcinoma and all other approved indications

Mar-ket

BMS PR Jan 28, 2010 - North American sales by BMS in 2009 were US$ 683 mln (- 9 % vs 2008); 2009 sales in Merck Serono territories were € 697 mln (+ 23 % vs 2008) corresponding to US$ 946.4 mln. Total sales of US$ 1,629 mln

1790

Vectibix; panitumu-mab

EGF-R Rec fully human IgG2 full mab

Takeda Pharmaceutical Co. & Amgen

Antibody 3rd line metastatic colorectal cancer et al

Mar-ket

Amgen PR Jan 25, 2010 - 2009 sales of US$ 233 mln (+ 52 % vs 2008)

Total = US$ 18.182 bln

http://www.pipelinereview.com/index.php/2010020332940/Financials/Strong-operating-performance-for-Roche-in-2009.html



http://www.pipelinereview.com/index.php/2010012832294/Financials/Strong-Operational-and-Strategic-Performance-in-Fourth-Quarter-Caps-Transformative-2009.html

http://www.pipelinereview.com/index.php/2010012532233/Financials/Amgens-Fourth-Quarter-2009-Adjusted-Earnings-Per-Share-Decreased-1-Percent-to-$1.05-Full-Year-2009-Adjusted-Earnings-Per-Share-Increased-8-Percent-to-$4.91.html



Group 2: TNF Antagonist Biologics

ID No.

Product Name


Class of Compound



Message

6605

Enbrel; etanercept

TNF antagonist

Dimeric fusion protein of soluble TNF-R + CH2 and CH3 domains of Fc of Ig

Amgen & Pfizer (acquired Wyeth) & Takeda Pharmaceutical Co.

Antibody Moderate to severe rheumatoid arthritis

Mar-ket

Amgen PR Jan 25, 2010 - Amgen in US and Canada: US$ 3,493 mln (- 3 % vs 2008); Wyeth: 6-mth revenues outside US and Canado of US$ 1,363 mln extrapolated to 12-mths sales of US$ 2,726 source Takeda: 9-mths (Apr-Dec) 2009 sales of Yen 24.5 bln (+ 20.5 %), extrapolated to 1-yr: Yen 32.6 bln source corresponding to US$ 361.4 mln. Total sales of US$ 6,580 mln

6587

Remicade; infliximab


Rec chimeric IgG1 mab

Centocor (J&J) & Merck & Co. (acquired Schering-Plough) & Mitsubishi Tanabe Pharma

Antibody Moderately to severely active rheumatoid arthritis

Mar-ket

Merck & Co 2009 Product Sales Feb 16, 2010 – Merck: US$ 2,327 mln (+ 9.9 %); J&J: US$ 3,088 mln (+ 9.9 % vs 2008) and exports to partners of US$ 987 mln source MTP’s forecast of fiscal year 2009 sales are Yen 46.8 bln source corresponding to US$ 519 mln. Total sales of US$ 5,934 mln

6571

Humira Pen; adalimumab;


Rec fully human mab

Abbott & Eisai Antibody Moderate to severe rheumatoid arthritis

Mar-ket

Abbott PR JAn 27, 2010 - 2009 sales of US$ 5,488 mln (+ 21.4 % vs 2008); Eisai reports YOY sales of Yen 4.8 bln (+ 311 %) source corresponding to US$ 53.2 mln

650 CIMZIA; certolizumab pegol; CDP-870

TNF-alpha (soluble and membrane bound)

PEGylated rec human-ized Fab' fragment

UCB Pharma (ex Celltech)

Antibody Moderate to severe Crohn's disease and RA

Mar-ket

UCB PR Mar 2, 2010 - 2009 sales were € 70 mln (+ 600 % vs 2008) corresponding to US$ 95.1 mln

Total: US$ 18.097 bln


http://www.wyeth.com/irj/servlet/prt/portal/prtroot/com.sap.km.cm.docs/wyeth_xml/home/news/announcements/1248346908863.pdf

http://www.takeda.com/pdf/usr/default/00_35799_2.pdf

http://www.pipelinereview.com/database/attachments/Merck%20&%20Co%202009%20Product%20Sales%20Feb%2016,%202010.pdf


http://www.mt-pharma.co.jp/e/ir/data/mtpc/2203/pdf/e2009_3rdQ.pdf

http://www.pipelinereview.com/index.php/2010012732270/Financials/Abbott-Reports-Double-Digit-Sales-and-Earnings-Growth-in-Fourth-Quarter-Issues-Strong-Earnings-Outlook-for-2010.html

http://www.eisai.co.jp/pdf/eir/emat/4523_100202e.pdf

http://www.pipelinereview.com/index.php/2010030232864/Financials/UCB-Solid-foundation-for-sustainable-growth.html



Group 3: Insulin - I

ID No.

Product Name


Class of Compound



Message

1379

Lantus; insulin glargine

Insulin receptor

Rhu basal insulin analog for once-daily SC injection

Sanofi-Aventis Protein Type 1 and Type 2 diabetes

Mar-ket

Sanofi-Aventis PR Feb 10, 2010 - 2009 sales of € 3,080 mln (+ 22.5 % vs 2008) corresponding to US$ 4,185 mln

1380

Actrapid (EU)/ Novolin (US); rhu insulin

Insulin receptor

Rhu insulin (short-acting) for injection, produced in S.cerevisiae


Mar-ket

Novo Nordisk PR Feb 2, 2010 - 2009 sales of human insulin product group was DKK 11,315 (- 5 % in local currencies vs 2008) corresponding to US$ 2,066 mln

1324

Humalog Mix 50:50; premix insulin lispro

Insulin receptor

Mixture of soluble rhu insulin analog (50 %) with insuline-protamine precipitate (50 %)


Mar-ket

Lilly 2009 Product Sales Jan 28, 2010 - 2009 sales of US$ 1,959 mln (+ 13 % vs 2008)

1223

NovoLog (US) / NovoRapid (EU); insulin aspart

Insulin receptor

Rhu insulin analog (rapid-acting) for injection, produced in S.cerevisiae

Novo Nordisk Protein Glycemic control in children and adults with diabetes mellitus

Mar-ket

Novo Nordisk PR Feb 2, 2010 - 2009 sales of DKK 9.749 mln (+ 22 % in local currencies vs 2008) corresponding to US$ 1,780 mln

http://en.sanofi-aventis.com/binaries/20100210_Results2009_en_tcm28-27173.pdf

http://www.pipelinereview.com/index.php/2010020232365/Financials/Novo-Nordisk-increased-operating-profit-by-21-in-2009.html

http://www.pipelinereview.com/database/attachments/Lilly%202009%20Product%20Sales%20Jan%2028,%202010.xlsx





Group 3: Insulin - II

ID No.

Product Name


Class of Compound



Message

6984

NovoMix 50; premix insulin aspart

Insulin receptor

Soluble (50 %) and protamine-crystallized (50 %) rhu insulin analog aspart


Mar-ket

Novo Nordisk PR Feb 2, 2010 - 2009 sales of product group was DKK 6,499 (+ 15 % in local currencies vs 2008) corresponding to US$ 1,187 mln

8893

Humulin 50:50; premix human insulin

Insulin receptor

Rhu insulin produced in E.coli, mix of 50 % soluble human insulin and 50 % insulin isophane suspension


Mar-ket

Lilly 2009 Product Sales Jan 28, 2010 - 2009 sales of US$ 1,022 mln (- 4 % vs 2008)

1238

Levemir; insulin detemir

Insulin receptor

Rec human basal insulin analogue for once-daily injection

Novo Nordisk Protein Children and adults with insulin-dependent diabetes

Mar-ket

Novo Nordisk PR Feb 2, 2010 - 2009 sales of DKK 5,223 (+ 35 % in local currencies vs 2008) corresponding to US$ 954 mln

6982

Apidra; insulin glulisine

Insulin receptor

Mealtime short acting rhu insulin analog

Sanofi-Aventis Protein Type 1 and 2 diabetes mellitus

Mar-ket

Sanofi-Aventis PR Feb 10, 2010 - 2009 sales of € 137 mln (+ 38.8 % vs 2008) corresponding to US$ 185.9 mln






http://en.sanofi-aventis.com/binaries/20100210_Results2009_en_tcm28-27173.pdf



Group 4: Erythropoiesis Stimulating Agents (ESA) - I

ID No.

Product Name


Class of Compound



Message

52 Aranesp; darbepoetin alfa


Engineered variant of rec hu hormone + AutoInjector

Amgen Protein Chronic kidney disease (once monthly) and all other approved indications

Mar-ket

Amgen PR Jan 25, 2010 - 2009 sales of US$ 2,652 mln (- 15 % vs 2008)

165 NESP; darbepoetin; KRN-321


Glycoengineered rhu protein

Kyowa Hakko Kirin Pharma (from Amgen)

Protein Renal anemia Mar-ket

Kyowa Hakko Kirin 2009 Results Presentation Jan 29, 2010 - Combined sales of NESP and ESPO in 2009 were Yen 39.6 bln (+ 15 % vs 2008) = US$ 438.4 mln

161 Epogen; epoetin alfa


Rhu erythropoietin alfa

Amgen Protein Renal anemia and all other approved indications

Mar-ket

Amgen PR Jan 25, 2010 - 2009 sales of US$ 2,569 mln (+ 5 % vs 2008)

162 ESPO; epoetin alfa


Rhu protein Kyowa Hakko Kirin Pharma (from Amgen)


Kyowa Hakko Kirin 2009 Results Presentation Jan 29, 2010 - Combined sales of NESP and ESPO in 2009 were Yen 39.6 bln

1899

Procrit / Eprex / Erypo; epoetin alfa


Rec human glycoprotein

Ortho Biotech / Janssen-Cilag (J&J) (from Amgen)

Protein Chemotherapy induced anemia and all other approved indications

Mar-ket

J&J 2009 Product Sales Jan 26, 2010 - 2009 sales were US$ 2,245 mln (- 8.7 %)

163 Neo-Recormon; epoetin beta


Rhu protein Roche Protein Renal anemia and all other approved indications

Mar-ket

Roche PR Feb 3, 2010 - 2009 international sales of NeoRecormon except US and Japan were CHF 1045 mln corresponding to US$ 971 mln: combined sales of Epogin and NeoRecormon were CHF 1560 mln (- 11 % vs 2008)


http://ir.kyowa-kirin.co.jp/data/current/report-962-datafile.pdf





http://www.pipelinereview.com/database/attachments/J&J%202009%20Product%20Sales%20Jan%2026,%202010.pdf





Group 4: Erythropoiesis Stimulating Agents - II

ID No.

Product Name


Class of Compound



Message

164 Epogin; Epoch; epoetin beta


Rhu erythropoietin beta

Roche (Chugai)

Protein Renal anemia. Chemotherapy induced anemia

Mar-ket

Roche PR Feb 3, 2010 - 2009 sales in Japan of Epogin were CHF 515 mln (-1% vs 2008) corresponding to US$ 479 mln

207 Mircera; Methoxy polyethylene glycol-epoetin beta; CERA


Continuous erythro-poiesis receptor activator (pegylated)

Roche Protein Renal anemia due chronic kidney disease +/- dialysis

Mar-ket

Roche PR Feb 3, 2010 - Worldwide sales in 80 countries in 2009 was CHF 179 mln (+ 252 % vs 2008) corresponding to US$ 166 mln

173 Binocrit / Epoetin alfa Hexal / Abseamed; epoetin alfa


Rhu erythro-poietin

Sandoz (Novartis) & Medice


Novartis Results Presentation Jan 26, 2010 - 2009 sales of approx. US$ 50 mln (+ approx. 60 % vs 2008)

166 Dynepo; epoetin delta


Rhu protein from gene activation technology (human cell line)

Shire Protein Renal anemia. Renal anemia with two new dosing regimens

Mar-ket

Shire PR Feb 19, 2009 - Shire ceased commercialization of Dynepo at the end of 2008




http://www.pipelinereview.com/database/attachments/Novartis%20Investor%20Presentation%20Jan%2026,%202010.pdf


http://www.shire.com/shire/documents/Q408pressreleasefinal19Feb09.pdf



Group 5: Interferon beta

ID No.

Product Name


Class of Compound



Message

1556

Avonex; interferon beta-1a


Rhu protein for IM injection once a week

Biogen Idec Protein Relapsing forms of multiple sclerosis

Mar-ket

Biogen Idec PR Feb 9, 2010 - 2009 sales of US$ 2,323 mln (+ 5 % vs 2008)

1534

Rebif; interferon beta-1a


Rhu protein (prefilled syringe)

Merck Serono Protein Relapsing forms of multiple sclerosis

Mar-ket

Merck KGaA PR FEb 23, 2010 - 2009 sales of € 1,537 mln (+ 15 % vs 2008) corresponding to US$ 2,087 mln

1501

Betaseron / Betaferon; interferon beta-1b


Rhu protein Berlex & Bayer Schering Pharma

Protein All relapsing forms of multiple sclerosis

Mar-ket

Bayer Briefing Feb 26, 2010 - 2009 sales of € 1,214 mln (+ 5.7 % in local currencies vs 2008) corresponding to US$ 1,649 mln


http://www.pipelinereview.com/index.php/2010020932516/Financials/Biogen-Idec-Reports-Full-Year-and-Fourth-Quarter-2009-Results.html

http://www.merck.de/en/media/extNewsDetail.html?newsId=8FB6CB9EE0627BA2C12576D2005DF6D1&newsType=1

http://www.pipelinereview.com/database/attachments/Bayer%20Briefing%20Feb%2026,%202010.pdf



Group 6: Coagulation Factors

ID No.

Product Name


Class of Compound



Message

106 Advate; octocog alfa; antihemo-philic factor plasma/ albumin-free

Coagulation factor VIII replacement

Rec full length coagulation factor VIII plasma/ albumin free

Baxter Healthcare

Protein Hemophilia A

Mar-ket

Baxter 2009 Product Line Sales Jan 28, 2010 - Combined sales of Advate and Recombinate in 2009 were US$ 2,058 mln (+ 5 % vs 2008) continued customer adoption of Advate over Recombinate

117 NovoSeven; eptacog alfa; rFVII

Substitution of coagulation F. VIIa

Rhu activated factor VII in BHK

Novo Nordisk (from Zymogenetics)

Protein Hemorrhage in hemophiliacs with alloantibodies

Mar-ket

Novo Nordisk PR Feb 2, 2010 - 2009 sales of DKK 7,072 mln (+ 10% in local currencies vs 2008) corresponding to US$ 1,292 mln

119 Kogenate FS (BAY 14-2222) + BIO-SET


Rhu protein formulated with sucrose (BHK)

Bayer Schering Pharma

Protein Hemophilia A Mar-ket

Bayer Briefing Feb 26, 2010 - 2009 sales: € 888 mln (+ 3.2 % in local currencies vs 2008) = US$ 1,207 mln (incl. transfer sales to CSL)

150 BeneFix; nonacog alfa

F. IX substitution

Rec hu protein

Pfizer (acquired Wyeth) & Biovitrum

Protein Hemophilia B Mar-ket

Pfizer 2009 Financial Report - Sales in last 2.5 mths of US$ 98 mln, extrapolated to 12-mths sales of approx. US$ 479 mln

10106

Helixate FS / Helixate NexGen


Rhu protein formulated with sucrose

CSL Behring (manufactured by Bayer Schering Pharma)


CSL Presentation Feb 12, 2010 - Sales in H1 (Jul-Dec) of FY 2009/20 were US$ 247 mln and in H1 of 2009 were US$ 220 mln source calendar year 2009: US$ 467 mln

114 Xyntha (USA); moroctocog alfa (AF-CC)

Substitution of coagulation factor VIII

Albumin free (AF) rhu B-domain deleted factor VIII

Pfizer (acquired Wyeth) & Biovitrum


Pfizer 2009 Financial Report - Combined product sales of Xyntha/ Refacto in last 2.5 mths after acquisition of Wyeth by Pfizer was US$ 47 mln extrapolated to 12-mths sales: approx US$ 225 mln


http://www.pipelinereview.com/database/attachments/Baxter%202009%20Product%20Sales%20Jan%2028,%202010.pdf

http://www.pipelinereview.com/database/attachments/Baxter%202009%20Product%20Sales%20Jan%2028,%202010.pdf


http://www.pipelinereview.com/database/attachments/Bayer%20Briefing%20Feb%2026,%202010.pdf

http://media.pfizer.com/files/annualreport/2009/financial/financial2009.pdf

http://www.csl.com.au/docs/608/748/1H10%20results%20presentation%20FINAL%20NN.pdf

http://www.csl.com.au/docs/970/717/1H09%20results%20presentation%20FINAL%20NN.pdf




Group 7: Granulocyte Colony Stimulating Factor (G—CSF)

ID No.

Product Name


Class of Compound



Message

1874

Neulasta; pegfilgrastim

G-CSF receptor

Pegylated rec methionyl human G-CSF

Amgen Protein Myelosuppressive chemotherapy with at least 17 % risk of febrile neutropenia

Mar-ket

Amgen PR Jan 25, 2010 - 2009 sales of US$ 3,355 mln (+ 1 % vs 2008)

1943

Neupogen; filgrastim

G-CSF receptor

Rhu protein Amgen Protein Neutropenia Mar-ket

Amgen PR Jan 25, 2010 - 2009 sales were US$ 1,288 mln (- 4 % vs 2008)

9986

Neu-up; nartograstim

G-CSF receptor

Rhu protein Kyowa Hakko Kirin Pharma

Protein Neutropenia Mar-ket

Kyowa Hakko Kirin 2009 Results Presentation Jan 29, 2010 - Combined sales of Neu-up and Gran in 2009 were Yen 13.8 bln (- 3 % vs 2008) corresponding to US$ 153 mln

9983

Gran; filgrastim

G-CSF receptor

Rhu protein Kyowa Hakko Kirin Pharma (from Amgen)

Protein Neutropenia Mar-ket

Kyowa Hakko Kirin 2009 Results Presentation Jan 29, 2010 - Combined sales of Neu-up and Gran in 2009 were Yen 13.8 bln (- 3 % vs 2008)

2345

Neutrogin; lenograstim

G-CSF receptor

Rhu protein Chugai & Roche

Protein Chemotherapy-induced neutropenia

Mar-ket

Roche Results Presentation Feb 3, 2010 - 2009 sales by Chugai in Japan were CHF 385 mln (- 14 % vs 2008) = US$ 358 mln

9378

Zarzio; filgrastim

G-CSF receptor

Generic equivalent of Neupogen from Amgen

Sandoz (Novartis)

Protein Neutropenia

Mar-ket

Novartis Results Presentation Jan 26, 2010 - 2009 sales of approx. US$ 8 mln (launched during 2009 in Germany, France, Spain, Poland and Austria)








http://www.pipelinereview.com/database/attachments/Roche%202009%20Results%20Presentation%20Feb%203,%202010.pdf






Group 8: Anti-Inflammatory Antibodies

ID No.

Product Name


Class of Compound



Message

1476

Tysabri; Antegren; natalizumab; AN100226

Alpha4/beta1/7 integrin

Rec humanized IgG4 mab

Biogen Idec & Elan

Antibody RR multiple sclerosis

Mar-ket

Biogen Idec PR Feb 9, 2010 - 2009 global in-market sales of US$ 1,060 mln (+ 30 % vs 2008) of which 509 mln were generated in the US and 551 mln outside the US

90 Xolair; omalizumab;

IgE Rec humanized mab

Roche (Genentech) & Novartis

Antibody Severe allergic asthma in adults and adolescents (age 12 or above)

Mar-ket

Roche Results Presentation Feb 3, 2010 - US sales by Roche: CHF 620 mln (+ 10 % vs 2008) = US$ 576 mln; Novartis sales: US$ 338 mln (+ 65 % in local currencies) source Total sales of US$ 914 mln

6537

Orencia; abatacept; CTLA4-Ig

B7-1 (CD80) and B7-2 (CD86)

Rec fusion protein of CTLA4+ Fc of IgG1 (hinge, CH2 + CH3)

Bristol-Myers Squibb

Antibody Adult rheumatoid arthritis and juvenile idiopathic arthritis

Mar-ket

BMS PR Jan 28, 2010 - 2009 sales of US$ 602 mln (+ 37 % vs 2008)

37 Soliris; eculizumab; H5G1.1

Complement C5 antagonist

Rec human-ized (hybrid IgG2/4) full mab

Alexion Phar-maceuticals

Antibody Paroxysmal nocturnal hemoglobinuria (PNH)

Mar-ket

Alexion Pharmaceuticals PR Feb 11, 2010 - 2009 sales of US$ 386.8 mln (+ 46 % vs 2008)

6545

RoActemra (EU); Actemra; tocilizumab

Interleukin-6 receptor (IL-6R) antagonist

Rec humanized mab

Roche (Chugai)

Antibody Moderate to severe rheuma-toid arthritis (RA)

Mar-ket

Roche PR Feb 3, 2010 - Available in 25 countries, 2009 sales were CHF 146 mln (+ 289 % vs 2008) corresponding to US$ 135.5 mln

6546

ARCALYST; rilonacept; Il-1 trap

Interleukin-1 (IL-1) antagonist

Trap (2 IL receptor do-mains + CH2 +CH3 of Fc)

Regeneron Pharma-ceuticals

Antibody Cryopyrin-asso-ciated periodic syndromes (CAPS)

Mar-ket

Regeneron Pharmaceuticals PR Feb 18, 2010 - 2009 net product sales of US$ 18.4 mln (+ 192 % vs 2008)


http://www.pipelinereview.com/index.php/2010020932516/Financials/Biogen-Idec-Reports-Full-Year-and-Fourth-Quarter-2009-Results.html



http://www.pipelinereview.com/index.php/2010012832294/Financials/Strong-Operational-and-Strategic-Performance-in-Fourth-Quarter-Caps-Transformative-2009.html

http://www.pipelinereview.com/index.php/2010021132615/Financials/Alexion-Reports-Fourth-Quarter-and-Full-Year-2009-Results.html

http://www.pipelinereview.com/index.php/2010021132615/Financials/Alexion-Reports-Fourth-Quarter-and-Full-Year-2009-Results.html


http://www.pipelinereview.com/index.php/2010021832953/Financials/Regeneron-Reports-Full-Year-and-Fourth-Quarter-2009-Financial-and-Operating-Results.html

http://www.pipelinereview.com/index.php/2010021832953/Financials/Regeneron-Reports-Full-Year-and-Fourth-Quarter-2009-Financial-and-Operating-Results.html



Group 9 Human Growth Hormone (hGH)

ID No.

Product Name


Class of Compound



Message

1289

Genotropin; somatropin

hGH) receptor

Rhu protein with SC inj. devices

Pfizer Protein Growth hormone deficiency

Mar-ket

Pfizer 2009 Financial Report - 2009 sales of US$ 887 mln (- 0.6 % vs 2008)

1291

Norditropin; somatropin

hGH receptor Rhu protein Novo Nordisk Protein Growth hormone deficiency

Mar-ket

Novo Nordisk PR Feb 2, 2010 - DKK 4,401 mln (+ 10 % in local currencies) = US$ 804 mln

1290

Humatrope; somatropin

hGH receptor Rhu protein for SC injection

Eli Lilly Protein Growth hormone deficiency

Mar-ket

Lilly 2009 Product Sales Jan 28, 2010 - 2009 sales of US$ 448.8 mln (- 4.1 % vs 2008)

1288

Nutropin; Nutropin AQ; somatropin

hGH receptor Rhu protein Genentech (Roche)

Protein Growth hormone deficiency

Mar-ket

Roche Results Presentation Feb 3, 2010 - 2009 sales in Roche territories were CHF 400 mln (+ 3 % in local currencies vs 2008) corresponding to US$ 371.8 mln

1292

Saizen; somatropin

hGH receptor Rhu protein Merck Serono Protein Growth hormone deficiency

Mar-ket

Merck KGaA PR Feb 23, 2010 - 2009 sales of € 191 mln (+ 11 % vs 2008) corresponding to US$ 259.6 mln

1239

Omnitrope; somatropin

Human growth hormone (hGH) receptor

Rhu protein (Generic equivalent of Genotropin from Pfizer

Sandoz (Novartis)

Protein Growth hormone deficiency

Mar-ket

Novartis Results Presentation Jan 26, 2010 - 2009 sales of approx. US$ 60 mln (+ approx. 55 % vs 2008)

8750

Nutropin AQ; somatropin

hGH receptor Rhu protein Ipsen (from Genentech)

Protein Growth hormone defiency

Mar-ket

Ipsen PR Feb 1, 2010 - 2009 sales of € 40.4 mln (+ 26.5 % on a constant currency exchange rate basis vs 2008) corresponding to US$ 54.8 mln











http://www.pipelinereview.com/index.php/2010020132364/Financials/Ipsens-Fourth-Quarter-and-Full-Year-2009-Sales.html



Group 10: Interferon alpha

ID No.

Product Name


Class of Compound



Message

861 Pegasys; peg-interferon alfa-2a


Pegylated rhu protein

Roche Protein Chronic hepatitis C virus infection + Copegus

Mar-ket


794 PegIntron; pegylated interferon alfa-2b


Pegylated (12 kDa) rec human protein

Merck & Co. (acquired Schering-Plough)

Protein Hepatitis C virus infection plus/minus ribavirin; retreatment after previous IFN treatment failure

Mar-ket

Merck & Co 2009 Product Sales Feb 16, 2010 - 2009 sales of US$ 844 mln (- 7.7 % vs 2008)

920 Intron A; interferon alpha-2b


Rhu protein Merck & Co. (acquired Schering-Plough)

Protein HCV infection Mar-ket

Merck & Co 2009 Product Sales Feb 16, 2010 - 2009 sales of US$ 231 mln (-1 1.3 % vs 2008)









Group 11: Enzyme Replacement Therapies

ID No.

Product Name


Class of Compound



Message

7822

Cerezyme; imiglucerase

Beta-gluco-cerebrosidase enzyme replacement

Rhu protein Genzyme Protein Type 1 Gaucher disease

Mar-ket

Genzyme PR Jan 12, 2010 - 2009 sales were US$ 793 mln (- 34 % vs previous year) - due to manufacturing problems

1176

Fabrazyme; agalsidase beta

Alpha-galactosidase A enzyme replacement

Rhu protein Genzyme Protein Fabry disease Mar-ket

Genzyme PR Jan 12, 2010 - 2009 sales were US$ 431 mln (- 13 % vs previous year) - due to manufacturing problems

1157

Elaprase; idursulfase; iduronate-2-sulfatase

Iduronate-2-sulfatase enzyme replacement

Rhu protein Shire & Genzyme

Protein Hunter syndrome (MPS-II)

Mar-ket

Shire PR Feb 19, 2010 - 2009 sales of US$ 353 mln (+ 20 % on a constant exchange rate basis vs 2008)

1192

Lumizyme; Myozyme; alglucosidase alpha

Alglucosidase alpha replacement

Rec hu enzyme

Genzyme Corp

Protein Pompe disease Mar-ket

Genzyme PR Jan 12, 2010 - 2009 sales of US$ 324 mln (+ 9 % vs previous year)

1381

Replagal; GA-agalsida-se alfa

Alpha-galactosidase ERT

Rhu protein Shire & Dainippon Sumitomo

Protein Fabry disease Mar-ket

Shire PR Feb 19, 2010 - US$ 194 mln (+ 16 % on a constant exchange rate basis vs 2008)

1161

Naglazyme; galsulfase; rhASB

Arylsulfatase B enzyme replacement

Rhu protein Biomarin Pharmaceutical & AnGes MG

Protein Mucopolysaccharidosis VI (MPS VI)

Mar-ket

BioMarin Pharmaceuticals PR Feb 24, 2010 - 2009 sales were US$ 168.7 mln (+ 27.1 % vs 2008)

1159

Aldurazyme; laronidase

Alpha-L-iduronidase enzyme replacement

Rhu protein Biomarin Phar-maceuticals & Genzyme

Protein Mucopolysaccharidosis I (MPS I)

Mar-ket

BioMarin Pharmaceuticals PR Feb 24, 2010 - 2009 sales reported by Genzyme were US$ 155.1 mln (+ 2.5 % vs 2008)

1385

VPRIV; velaglucer-ase alfa

Human gluco-cerebrosidase ERT

Rhu protein, gene-activated

Shire Protein Type 1 Gaucher's disease

Mar-ket

Shire Presentation Feb 19, 2010 - 2009 sales of US$ 3 mln; launches in EU and US start in 2010


http://www.pipelinereview.com/index.php/2010011232053/Financials/Genzyme-Reports-Fourth-Quarter-Revenue.html


http://www.pipelinereview.com/index.php/2010021932724/Financials/Excellent-results-in-a-transformational-year-for-Shire-core-product-sales-up-25.html


http://www.pipelinereview.com/index.php/2010021932724/Financials/Excellent-results-in-a-transformational-year-for-Shire-core-product-sales-up-25.html

http://www.pipelinereview.com/index.php/2010022432769/Financials/BioMarin-Announces-Fourth-Quarter-and-Full-Year-2009-Financial-Results.html




http://www.pipelinereview.com/database/attachments/Shire%202009%20Results%20Presentation%20Feb%2019,%202010.pdf



Group 12: Ophthalmic Antibody

ID No.

Product Name


Class of Compound



Message

6306

Lucentis; ranibizumab; RG3645; RG-3645

Vascular endothelial growth factor (VEGF)

Rec humanized Fab for intravitreal injection

Roche (Genentech) & Novartis

Antibody Wet age-related macular degeneration (AMD)

Mar-ket

Roche PR Feb 3, 2010 - US sales by Roche (Genentech) in 2009 were CHF 1,198 mln (+ 24 % vs 2008) corresponding to US$ 1,112 mln; 2009 sales by Novartis in more than 80 countries were US$ 1,232 mln (+ 47 % in local currencies vs 2008) source Total sales of US$ 2,344 mln

Group 13: Follicle Stimulating Hormone (FSH)

ID No.

Product Name


Class of Compound



Message

1319

Puregon / Follistim; follitropin beta

Follicle Stimulating Hormone (FSH) receptor

Rhu glycoprotein produced in CHO cells, available in vials and cartridges

Merck & Co. (acquired Schering-Plough) (ex Organon))

Protein Development of multiple follices in ovulatory women and in anovulatory infertile women

Mar-ket

Merck & Co 2009 Product Sales Feb 16, 2010 - 2009 sales of US$ 546 mln (- 5.4 % vs 2008)

1260

Gonal-f; rec follitropin alpha; GONALEF; FSH

Follicle Stimulating Hormone (FSH)

Rec human protein

Merck Serono Protein Induction of ovulation and pregnancy in functionally infertile pts

Mar-ket

Merck KGaA PR Feb 23, 2010 - 2009 sales of € 486 mln (+ 5.8 % vs 2008) corresponding to US$ 660.4 mln








Group 14: Antiviral Antibody

ID No.

Product Name


Class of Compound



Message

734 Synagis; palivizumab; MEDI-493;

Epitope on RS virus

Rec humanized full mab

AstraZeneca (MedImmune)

Antibody Propylaxis of RSV infection

Mar-ket

AstraZeneca PR Jan 28, 2010 - 2009 sales of US$ 1,082 mln (- 12 %)

Group: Other Antibodies

ID No.

Product Name


Class of Compound



Message

217 ReoPro; abciximab

Glycoprotein IIb/IIIa antagonist

Fab fragment of chimeric mab 7E3

Eli Lilly & Centocor (J&J)

Antibody Adjunct to PCI (percutaneous coronary interventions)

Mar-ket

Lilly 2009 Product Sales Jan 28, 2010 - 2009 sales of US$ 231.5 mln (- 9.7 %)

http://www.pipelinereview.com/index.php/2010012832296/Financials/AstraZeneca-PLC-Fourth-Quarter-and-Full-Year-Results-2009.html





Group: Selected Proteins - I

ID No.

Product Name


Class of Compound



Message

440 Pulmozyme; dornase alfa

DNA Rhu enzyme delivered with nebulizer

Roche (Genentech)

Protein Cystic fibrosis Mar-ket

Roche Results Presentation Feb 3, 2010 - 2008 sales by Roche were CHF 501 mln (+ 5 % in local currencies vs 2008) corresponding to US$ 466 mln

10016

InductOs; rhBMP-2/ACS; dibotermin alfa applied to Absorbable Collagen Sponge

Bone regeneration

Rhu bone morphogenic protein on collagen matrix

Pfizer (acquired Wyeth) & Astellas Pharma

Medical device & biomaterial

Acute tibia fractures; lower back spine fusion surgery (plus cage)

Mar-ket

Medtronic PR Feb 23, 2010 - Medtronic sales of Biologics from Jan to Dec 2009 were US$ 866 mln of which Wyeth usually received 50 % = US$ 433 mln (+ 11 % vs 2008)

151 TNKase; Metalyse; tenecteplaseTNK-t-PA

Plasminogen activator

Rec engineered t-PA (3 aa substituted)

Roche (Genentech) & Boehringer Ingelheim

Protein Acute myocardial infarction

Mar-ket

Roche Results Presentation Feb 3, 2010 - 2009 sales Activase and TNKase in Roche territories were CHF 455 mln (+ 34 % in local currencies vs 2008) corresponding to US$ 423 mln; BI results not yet published

10063

Thyrogen; TSH alfa for injection

Thyroid hormone receptor stimulator

Rec human thyrotropin (TSH) for injection

Genzyme Protein Adjunctive treatment in thyroidectomy for well-differentiated thyroid cancer

Mar-ket

Genzyme PR Feb 17, 2010 - 2009 sales of US$ 170.6 mln (+ 15 % vs 2008)

64 Xigris; drotrecogin-alpha; rhu activated protein C

F. Va + F. VIIIa; PAI-1; TNF; thrombin

Rec hu protein

Eli Lilly & Teijin

Protein Severe sepsis Mar-ket

Lilly 2009 Product Sales Jan 28, 2010 - 2009 sales of US$ 127.3 mln (- 20.8 %)



http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MzI1OTZ8Q2hpbGRJRD0tMXxUeXBlPTM=&t=1



http://www.pipelinereview.com/index.php/2010021732667/Financials/Genzyme-Reports-Financial-Results-for-Fourth-Quarter-of-2009-and-Full-Year.html





Group: Selected Proteins - II

ID No.

Product Name


Class of Compound



Message

6686

Kineret; anakinra;

Interleukin-1 receptor (IL-1R) antagonist

Rhu protein (non-glycosylated, N-terminal methionin)

Biovitrum (from Amgen)

Protein Rheumatoid arthritis

Mar-ket

Biovitrum 2009 Results Presentation Feb 18, 2010 - 2009 global sales of SEK 440.7 mln corresponding to US$ 61.6 mln

1149

Increlex; mecasermin; rhIGF-1

Insulin-like growth factor-1 ( IGF-1) receptor agonist

Rhu growth factor

Ipsen (acquired Tercica)

Protein Severe forms of primary IGF deficiency (IGFD) in children

Mar-ket

Ipsen PR Feb 1, 2010 - 2009 sales of € 21 mln (+ 286 % on a constant currency exchange rate basis vs 2008) corresponding to US$ 28.5 mln

1785

Kepivance; palifermin; rhu KGF-1; FGF-7

Keratinocyte growth factor receptor

Rec human KGF

Biovitrum (from Amgen)

Protein Severe oral mucositis in pts with hematologic cancers undergoing bone marrow transplantation

Mar-ket

Biovitrum 2009 Results Presentation Feb 18, 2010 - 2009 global sales were SEK 109.9 mln corresponding to US$ 15.4 mln

http://www.pipelinereview.com/database/attachments/Biovitrum%202009%20Results%20Presentation%20Feb%2018,%202010.pdf







Group: Selected Peptides - I

ID No.

Product Name


Class of Compound



Message

10105

Copaxone; glatiramer acetate

MHC class II modulator

4-aa poly-peptide at 20 mg daily SC dose

Teva Phar-maceutical Industries & Sanofi-Aventis

Peptide Relapsing-remitting multiple sclerosis

Mar-ket

Teva PR Feb 16, 2010 - 2009 global in-market sales of US$ 2,826 mln (+ 25 % vs 2008)

10107

Botox; onabotuli-numtoxinA

Neuromus-cular transmission (SNAP-25 cleavage)

Neurotoxin from Clostridium botulinum type A

Allergan Phar-maceuticals & GlaxoSmith-Kline Japan & China)

Peptide Medical and esthetic indications

Mar-ket

Allergan SEC 10-K Feb 26, 2010 - 2009 Allergan sales of US$ 1,309.6 mln (vs 1,310.9 mln in 2008); 52 % for medical and 48 % for cosmetic indications

10021

Sandostatin LAR; octreotide/IM injection

Somatostatin receptor

Somatostatin analogue, once-monthly

Novartis Peptide Acromegaly; gastro-entero-pancreatic neuroendocrine (GEP NE) tumors

Mar-ket

Novartis PR Jan 26, 2010 - 2009 sales of US$ 1,155 mln (+ 7 % in local currencies vs 2008)

2403

Velcade; bortezomib; PS-341

Proteasome inhibitor

Modified dipeptidyl boronic acid

Takeda Pharmaceutical Co. (ex Millennium) & Johnson & Johnson (J&J)

Peptide Multiple myeloma and all other approved indications

Mar-ket

J&J 2009 Product Sales Jan 26, 2010 - 2009 sales ex US reported by J&J were US$ 933 mln (+ 18.6 % vs 2008)

1169

Forteo; teriparatide; rec hu PTH(1-34);

PTH receptor Rec variant of human parathyroid hormone

Eli Lilly Peptide Osteoporose in postmenopausal women and all other approved indications

Mar-ket

Lilly 2009 Product Sales Jan 28, 2010 - 2009 sales of US$ 816.7 mln (+ 4.9 % vs 2008)

2392

Lupron / Leuplin; leuprorelin

LH-RH agonist

Nonapeptide Takeda Pharmaceutical & Abbott

Peptide Prostate cancer Mar-ket

Abbott PR JAn 27, 2010 - Abbott reported 2009 sales in its territories of US$ 800 mln (+ 22.8 % vs 2008); Takeda territories not yet reported

http://www.pipelinereview.com/index.php/2010021632642/Financials/Teva-Reports-Record-Full-Year-2009-And-Fourth-Quarter-Results.html

http://files.shareholder.com/downloads/AGN/834367053x0xS1193125-10-43126/850693/filing.pdf

http://www.pipelinereview.com/index.php/2010012632234/Financials/Novartis-achieves-record-results-in-2009-as-momentum-from-recently-launched-products-drives-growth-across-its-entire-healthcare-portfolio.html





http://www.pipelinereview.com/index.php/2010012732270/Financials/Abbott-Reports-Double-Digit-Sales-and-Earnings-Growth-in-Fourth-Quarter-Issues-Strong-Earnings-Outlook-for-2010.html



Group: Selected Peptides - II

ID No.

Product Name


Class of Compound



Message

7948

Byetta; exenatide; LY2148568

GLP-1 receptor agonist

SC 39-aa synthetic peptide bid

Amylin Phar-maceuticals & Eli Lilly

Peptide Type 2 diabetes monotherapy et al

Mar-ket

Lilly PR Jan 28, 2010 - 2009 worldwide sales of US$ 796.5 mln (+ 6 % vs 2008)

10060

Decapeptyl SR; triptorelin acetate

LHRH agonist/ GnRH analog

Synthetic decapeptide with slow release formulation

Ipsen Peptide Locally advanced prostate cancer; endometriosis; uterine fibroids prior to surgery

Mar-ket

Ipsen PR Feb 1, 2010 - 2009 sales of € 250.5 mln (+ 1.4 % on a constant currency exchange rate basis vs 2008) corresponding to US$ 340 mln

231 Integrilin; eptifibatide

GP IIb/IIIa Cyclic heptapeptide

Merck & Co. (acquired S-P) & Takeda (ex Millennium)

Peptide Acute coronary syndrome

Mar-ket

Merck & Co 2009 Product Sales Feb 16, 2010 - 2009 sales of US$ 295 mln (- 6 % vs 2008)

1564

Dysport (EU); Reloxin (US); abobotuli-numtoxinA

Neuromus-cular transmission (SNAP-25 cleavage)

Peptide for injection

Ipsen Peptide Cervical dystony

Mar-ket

Ipsen PR Feb 1, 2010 - 2009 sales of € 163.8 mln (+ 18 % on constant currency exchange rate basis vs 2008) = US$ 222.4 mln; Ipsen's sales figure includes supply to Medicis and Galderma

1172

Somatuline Autogel / Depot; lanreotide acetate

Somatostatin analog

Peptide in ready-to-use prefilled syringe

Ipsen Peptide Acromegaly Mar-ket

Ipsen PR Feb 1, 2010 - 2009 sales of € 140 mln (+ 18.2 % on a constant currency exchange rate basis vs 2008) corresponding to US$ 190.2 mln

874 Fuzeon needle free device; enfuvirtide

HIV entry inhibitor (fusion of HIV with CD4)

Linear 36-aa peptide + needle-free device

Trimeris & Roche

Peptide HIV Mar-ket

Trimeris PR Feb 02, 2010 - 2009 sales as repoted by Roche were US$ 112.2 mln (- 33 % vs 2008)

1205

Symlin; pramlintide

Amylin receptor

Synthetic amylin analog

Amylin Phar-maceuticals

Peptide Type 1 and 2 diabetes

Mar-ket

Amylin Pharmaceuticals PR Jan 27, 2010 - 2009 sales of US$ 86.4 mln (vs 86.8 mln in 2008)






http://www.pipelinereview.com/index.php/2010020232403/Financials/Trimeris-Reports-Fourth-Quarter-2009-FUZEONR-Sales-Results.html

http://www.pipelinereview.com/index.php/2010012732293/Financials/Amylin-Pharmaceuticals-Reports-2009-Financial-Results.html

http://www.pipelinereview.com/index.php/2010012732293/Financials/Amylin-Pharmaceuticals-Reports-2009-Financial-Results.html



• To keep up-to-date.

Examine the who, what, when, where of biotechnology R&D.

• To benchmark your company against the competition

Keep en eye on your competitors’ projects and developments, in which stage they are, their achievements, handicaps, etc…and find out where you are standing in the market.

• To save time in your research

Get the crucial information, in a one-shot tabular screen grouped in Therapeutic Areas or Product Categories, and deepen easily in those articles in which you are interested with just one-click.

• To identify new business enterprises

Recognize new business opportunities: joint ventures, licensing partners, co-marketing partners, etc..

• To receive news right in time

Get your personal copy every monday delivered by e-mail.

Why should you use R&D Pipeline N ?

Learn more about R&D Pipeline News

R&D Pipeline News is your weekly tool for biopharmaceutical R&D analysis and it's available by annual subscription. R&D Pipeline News will keep you up-to-date with the latest R&D projects of the biopharmaceutical industry, with all the relevant treatment modalities and with competitive information about ongoing R&D projects for a given Target, Technology or Company.

The R&D information is presented in an easy- and rapid-to-screen tabular format and grouped either in Therapeutic Areas or Product Categories, saving you time in your research.

Where can I get a subscription?

At our Online Store: http://www.pipelinereview.com/store/periodicals.html

Or contact us at [email protected]

http://www.pipelinereview.com/store/periodicals.html

mailto:[email protected]

top 20 biologics 2009 rd pipeline news

Documents